Mirati Therapeutics’ CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX)
gorodenkoff/iStock via Getty Images Mirati Therapeutics, Inc. (NASDAQ:MRTX) is at the forefront of oncological biotechnology. Its star product is adagrasib, commercially known as Krazati, a drug for treating KRAS G12C-mutated non-small cell lung cancer, which obtained accelerated approval from the FDA. This successful drug got the interest of Bristol-Myers Squibb (BMY) to acquire MRTX for…